Reasons for Our Lack of Concern Regarding Microbot Medical's (NASDAQ:MBOT) Cash Burn Issue
Written by Emily J. Thompson, Senior Investment Analyst
Source: Yahoo Finance
Updated: 10 hour ago0mins
Investor Interest in Unprofitable Companies: Microbot Medical's share price has surged 142% over the past year, attracting investor attention despite its lack of profitability and cash burn concerns.
Cash Burn and Runway Analysis: The company reported a cash burn of $11 million over the last year, with a cash runway of approximately 7.3 years, indicating a manageable financial situation for shareholders.
Growth Investment and Future Considerations: Although Microbot Medical's cash burn increased by 23%, suggesting a focus on future growth, this could shorten its cash runway if spending continues to rise.
Raising Capital and Market Position: With a market capitalization of $159 million, Microbot Medical's cash burn represents a low percentage of its market value, indicating potential ease in raising additional funds through share issuance or borrowing.
MBOT.O
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on MBOT
Wall Street analysts forecast MBOT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MBOT is 12.00 USD with a low forecast of 12.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.460
Low
12.00
Averages
12.00
High
12.00
Current: 2.460
Low
12.00
Averages
12.00
High
12.00
Roth Capital
Kyle Bauser
Buy
initiated
$5.50
2025-12-03
New
Reason
Roth Capital
Kyle Bauser
Price Target
$5.50
2025-12-03
New
initiated
Buy
Reason
Roth Capital analyst Kyle Bauser initiated coverage of Microbot Medical with a Buy rating and $5.50 price target. The firm says the company's Liberty Endovascular Robotic System achieved FDA clearance in September and has begun commercial use in select U.S. hospitals ahead of a full market release in April 2026. Roth thinks the technology will be useful within procedures that require navigation of complex vascular anatomy while also reducing physical strain and radiation exposure.
H.C. Wainwright
Raghuram Selvaraju
Buy
maintain
$9 -> $12
2025-09-11
Reason
H.C. Wainwright
Raghuram Selvaraju
Price Target
$9 -> $12
2025-09-11
maintain
Buy
Reason
H.C. Wainwright analyst Raghuram Selvaraju raised the firm's price target on Microbot Medical to $12 from $9 and keeps a Buy rating on the shares after the FDA granted 510(k) clearance for the company's Liberty System. This is the first FDA-approved, single-use, remotely operated robotic system for peripheral endovascular procedures, the analyst tells investors in a research note. The firm says the initial addressable market comprises 2.5M peripheral endovascular procedures annually in the U.S.
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Reiterates
$9
2025-04-10
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Price Target
$9
2025-04-10
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Maintains
$7 → $9
2025-01-24
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Price Target
$7 → $9
2025-01-24
Maintains
Strong Buy
Reason
See All Ratings
About MBOT
Microbot Medical Inc. is a pre-commercial stage medical technology company. It has developed the single-use, fully disposable endovascular robotic system, which aims to eliminate traditional barriers to accessing advanced robotic systems. It specializes in the research, design and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. Using its LIBERTY technological platform, it is developing a fully disposable robot for various endovascular interventional procedures. The LIBERTY Endovascular Robotic Surgical System is designed to maneuver guidewires and over-the-wire devices (such as microcatheters) within the body’s vasculature. It eliminates the need for extensive capital equipment requiring dedicated Cath-lab rooms as well as dedicated staff. Its addressable markets for the LIBERTY Endovascular Robotic Surgical System include the peripheral interventional radiology, interventional cardiology and interventional neuroradiology markets.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
What is the significance of HC Wainwright's $12 price target for Microbot?
How does the LIBERTY robotic system improve peripheral vascular procedures?
Will the LIBERTY system achieve widespread adoption after its 2026 market release?
Can Microbot Medical's stock price rise due to the LIBERTY system launch?